Advertisement

Pharmaceutisch Weekblad

, Volume 10, Issue 1, pp 22–25 | Cite as

The bioavailability of Tamoplex® (tamoxifen)

Part 3. A steady-state study in breast cancer patients
  • P. H. Th. J. Slee
  • D. De Vos
  • D. Chapman
  • D. Stevenson
Short Communications
  • 114 Downloads

Abstract

The bioavailability of two tamoxifen preparations (Tamoplex® and Nolvadex®) was compared in a multiple dose two-way cross-over design in twelve breast cancer patients. The formulations were found to be bioequivalent. Mean steady-state serum levels of tamoxifen andN-desmethyltamoxifen were 133 ng/ml and 242 ng/ml, respectively, at a single daily dose of three tablets of Tamoplex® 10 mg and 128 ng/ml and 248 ng/ml, respectively, at a single daily dose of three tablets of Nolvadex® 10 mg. While there was a large interpatient as well as intrapatient variability in steady-state levels of tamoxifen andN-desmethyltamoxifen, their ratio appeared to be constant in the individual patient.

Key words

Bioavailability Breast neoplasms Drug evaluation Tamoxifen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guelen PJM, Stevenson D, Briggs RJ, De Vos D. The bioavailability of Tamoplex® (tamoxifen). Part 2. A single dose cross-over study in healthy male volunteers. Methods Find Exp Clin Pharmacol 1987;9:685–90.PubMedGoogle Scholar
  2. 2.
    Patterson JS, Settatree RS, Adam HK, Kemp JV. Serum concentrations of tamoxifen and major metabolite during long-term Nolvadex therapy, correlated with clinical response. In: Mouridsen H, Palshof T, eds. Breast cancer: experimental and clinical aspects. London: Pergamon, 1980:89–92.Google Scholar
  3. 3.
    McVie JG, Simonetti GPC, Stevenson D, Briggs RJ, Guelen PJM, De Vos D. The bioavailability of Tamoplex® (tamoxifen). Part 1. A pilot study. Methods Find Exp Clin Pharmacol 1986;8:505–12.PubMedGoogle Scholar
  4. 4.
    Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer; comparison of traditional and loading dose schedules. Cancer Treat Rep 1980;64:765–73.PubMedGoogle Scholar
  5. 5.
    Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E. Clinical pharmacology of tamoxifen in patients with breast cancer. Cancer 1981;48:876–82.PubMedGoogle Scholar
  6. 6.
    Golander Y, Sternson LA. Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma. J Chromatogr 1980;181:41–9.PubMedGoogle Scholar
  7. 7.
    Soininen K, Kleimola T, Elomaa I, Salmo M, Rissanen P. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients. J Int Res 1986;14:162–5.Google Scholar
  8. 8.
    Metzler CM, Huang DC. Statistical methods for bioavailability and bioequivalence. Clin Res Pract Drug Reg Affairs 1983;1:109–32.Google Scholar
  9. 9.
    Westlake WJ. Statistical aspects of comparative bioavailability trials. Biometrics 1979;35:273–80.PubMedGoogle Scholar
  10. 10.
    Spriet A, Beiler D. Table to facilitate determination of symmetrical confidence intervals in bioavailability trials with Westlake's method. Eur J Drug Metab Pharmacokinet 1978;2:129–32.Google Scholar
  11. 11.
    Rodda BE, Davis DL. Determining the probability of an important difference in bioavailability. Clin Pharmacol Ther 1980;28:247–52.PubMedGoogle Scholar
  12. 12.
    Fluehler H, Hirtz J, Moser HA. An aid to decisionmaking in bioequivalence assessment. J Pharmacokinet Biopharm 1981;9:235–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Fluehler H, Grieve AP, Mandallaz D, Mau J, Moser HA. Bayesian approach to bioequivalence assessment: an example. J Pharm Sci 1983:72:1178–81.PubMedGoogle Scholar
  14. 14.
    Hauck WW, Anderson S. A new statistical procedure for testing equivalence in two group comparative bioavailability trials. J Pharmacokinet Biopharm 1984;12:83–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Heel RC, Brogden RN, Speight TM, Avery GS. Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 1978;16:1–24.PubMedGoogle Scholar
  16. 16.
    Manni A, Arafah BUM. Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily. Cancer 1981;48:873–5.PubMedGoogle Scholar
  17. 17.
    Bratherton DG, Brown CH, Buchanan R, et al. A comparison of two doses of tamoxifen in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 1984;50:199–205.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1988

Authors and Affiliations

  • P. H. Th. J. Slee
    • 1
  • D. De Vos
    • 2
  • D. Chapman
    • 3
  • D. Stevenson
    • 3
  1. 1.Department of Clinical OncologySint Jozef ZiekenhuisAH Goudathe Netherlands
  2. 2.Medical DepartmentPharmachemie BVRN Haarlemthe Netherlands
  3. 3.The Robens InstituteUniversity of SurreyGuildfordUK

Personalised recommendations